Latest news with #GregCase
CNBC
9 hours ago
- Business
- CNBC
We reject the idea there's a risk that's 'not coverable', says Aon CEO Greg Case
Greg Case, Aon CEO, joins 'Closing Bell Overtime' to talk global volatility, its investor day, AI integration, and more.
Cision Canada
01-05-2025
- Business
- Cision Canada
Four Interconnected Megatrends Are Driving Global Uncertainty For Business and Society: Aon Report
DUBLIN, May 1, 2025 /CNW/ -- Aon plc (NYSE: AON), a leading global professional services firm, today released its Client Trends 2025 report, which features new insights about the interconnectedness of four megatrends – Trade, Technology, Weather and Workforce – driving complexity, volatility and uncertainty for business and society. "The megatrends of Trade, Technology, Weather and Workforce are creating unprecedented challenges for business leaders, who risk decision paralysis when urgent action is needed," said Greg Case, president and CEO of Aon. "The interconnectedness of these trends means that leaders need access to integrated data and analytics, capabilities and expertise to effectively respond to increasingly linked risk and people issues." Aon's Client Trends 2025 report draws on the firm's Risk Capital and Human Capital expertise to offer a fresh perspective on how these trends intersect and impact decision making. The analysis looks at specific connection points between the trends, including with: Trade and Technology: The intersection of Technology and Trade are fuelling innovation that will deliver much-needed efficiencies in global supply chains. However, with new technology comes significant risks that must be properly managed. Artificial intelligence (AI) plays a vital role in helping move global trade through increasingly complex regulatory challenges, trade laws, privacy regulations and threats from cyber attacks and potential global trade wars. Technology and Workforce: The integration of AI within human resources functions is reshaping job roles and skill requirements across industries. Organizations are increasingly utilizing AI to optimize processes like talent acquisition and employee engagement. This shift not only enhances efficiency but focuses on upskilling employees to work alongside AI. As companies work to capitalize upon this transformation, are evolving their workforce with the necessary technical and maintaining critical human oversight to drive innovation and effective decision-making. Weather and Workforce: Extreme weather events are becoming more frequent and costly. According to Aon's 2025 Climate and Catastrophe Insight report, global economic losses in 2024 amounted to $368 billion. At the same time, employers are more concerned than ever about employee wellbeing, retention and productivity. Employees who work outside face health risks from heatwaves, air quality implications from wildfires and more. Not only can weather events affect employee's physical health, their emotional and financial wellbeing may also be at risk. Weather and Trade: The effects of climate volatility on global trade is another growing risk. This was starkly illustrated by the severe flooding in Spain and its impact on the automotive industry in 2024. Flooding disrupted production and logistics, highlighting the interconnectedness of supply chains and the financial risks posed by extreme weather events. In response, clients are integrating climate risk assessments into their strategic planning and developing diversified supply chains. By understanding and anticipating the impacts of weather-related disruptions, organizations are enhancing their resilience and protecting their trade operations in an increasingly unpredictable environment. About Aon Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses. Media Contact [email protected] Toll-free (U.S., Canada and Puerto Rico): +1 833 751 8114 International: +1 312 381 3024 SOURCE Aon plc
Yahoo
30-04-2025
- Business
- Yahoo
Aon Unveils First Workforce-Focused Analysis on GLP-1s: Medications and Holistic Support Can Transform Workforce Health and Bend the Cost Curve
Firm also sets new standard in employee health by combining GLP-1 medications and holistic support to drive adherence and sustainable outcomes for Aon's U.S. colleagues in collaboration with eMed CHICAGO, April 30, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today released findings from a multi-year study of U.S. commercial health claims data for more than 50 million commercially insured lives. The analysis highlights a significant opportunity to reduce healthcare costs for employers and enhance overall workforce health through a comprehensive obesity management program that includes GLP-1 medications. Drawing on its deep investments in health data and analytics, Aon provides data-driven workforce insights that help employers reduce costs, maximize productivity and improve employee health. For this analysis, Aon leveraged its Health Risk Analyzer to quantify the opportunity and impact of GLP-1 medications. As part of its commitment to advancing workforce wellbeing, Aon also announced the launch of its own GLP-1 weight management program for U.S. employees. The program combines affordable access to treatment with virtual support and adherence tools, addressing one of the most urgent and costly health challenges facing employers today. "Obesity is an escalating global epidemic, impacting nearly 40 percent of U.S. adults, contributing to more than 60 chronic conditions and costing the U.S. economy up to $1.72 trillion annually," said Greg Case, CEO of Aon. "Addressing this issue is not only a public health opportunity but also a workforce and economic imperative." Case continued, "Our analysis shows that GLP-1 medications, when paired with a holistic adherence program, represent a once-in-a-generation opportunity to prevent and manage chronic disease, improve quality of life and bend the healthcare cost curve. At Aon, we're already acting on these insights with our own GLP-1 weight management program to shape a smarter, more sustainable approach to workforce health. We invite others to join us in delivering meaningful improvements in health outcomes and long-term economic value." The Impact of GLP-1s: Health Improves, Cost Curve BendsTo help companies quantify the opportunity and impact of GLP-1 coverage, Aon leveraged a proprietary methodology and the firm's Health Risk Analyzer to evaluate an extensive dataset of medical and Rx claims data from over 50 million commercially insured lives, including 139,000 prescribed GLP-1 users from 2022-2024. Aon's early analysis reveals: A Bend in the Cost Curve: After the widely reported initial jump in costs related to initiation of GLP-1 medications, cost growth rates diverge from the GLP-1 treatment group, trending at half the rate of a precisely matched control group in the last 12 months of the analysis period. Outside the cost of the treatment, Aon observed a seven-percentage point improvement in medical spend growth for GLP-1 users in the second year. If this trend improvement is sustained over future periods, it implies significant positive impacts on population health and economic impacts extending beyond healthcare costs to reductions in absenteeism and disability and improved productivity. Reduced Cardiovascular Events and Improved Health: GLP-1 users experienced a 44 percent reduction in risk of hospitalizations caused by major adverse cardiovascular events (e.g., stroke, heart attack and heart failure) over the 24 months following therapy initiation. Other notable health improvements included lower incidence of claims for pneumonia, inflammatory bowel disease, osteoporosis, and alcohol and substance use disorders compared to a precisely matched control group. The analysis also showed GLP-1 users had elevated claims activity in certain arthritic conditions, thyroid and esophageal disorders, and sleep-wake disorders. Further research and analysis may show that by losing weight, patients accessed a broader spectrum of treatments, which translated to elevated utilization of services. "When you consider the indirect costs of obesity, such as the treatment of comorbidities and absenteeism, the overall economic burden is striking," said Farheen Dam, head of Health Solutions for North America at Aon. "Our preliminary insights show that GLP-1s – when paired with a wellbeing and adherence program that includes nutrition, exercise and mental health resources – can reduce long-term healthcare expenditures and even enhance workforce productivity." Aon will share the highlights of its health claims analysis at the Milken Institute Global Conference on May 5. The plenary session, "In Service of a Healthier Tomorrow," will examine how prevention, data, biomedical research, health financing and cross-sector partnerships can drive better health outcomes and capture economic value at scale. "Aon's analysis underscores the critical role that innovative, data-driven approaches can play in tackling one of the most pressing health challenges of our time," said Esther Krofah, executive vice president, Milken Institute Health. "By quantifying both the health and economic benefits of GLP-1 access, this work not only advances the dialogue around obesity management in the U.S. workforce, it also paves the way for scalable, global solutions that prioritize prevention and long-term impact." Aon Leading by Example: De-Stigmatizing and Subsidizing GLP-1s for Aon's U.S. Employee PopulationAs part of its leadership in employee wellbeing, Aon has launched a subsidized GLP-1 weight management benefit program for its U.S. workforce with eMed, an innovator in population health. This collaboration is designed to drive adherence and sustainable outcomes for employees by offering holistic support. eMed's wellness program uses AI tools to capture patient biometrics, offers at-home blood tests for maximum convenience and provides access to weekly virtual check-ins and 24/7 side effect management. "Making this investment is essential to delivering value and achieving results," said Lisa Stevens, chief administrative officer of Aon. "We're proving that it's possible to offer access to GLP-1s affordably and with dignity — and that doing so can benefit both people and the bottom line." The Road Ahead: Advancing Analytics to Support Better DecisionsAon works with employers in modeling the long-term business impact of GLP-1 adoption by providing customized claims analysis and global workforce impact modeling and planning. Aon emphasizes a comprehensive data-backed and human capital-focused approach to capture the transformative effects on health and productivity. This empowers employers to consider the full value of obesity management and make better decisions. By working with forward-thinking organizations, Aon aims to revolutionize chronic condition prevention and redefine workforce health investment, setting a new benchmark for the industry. For more about Aon's Health Solutions visit: Health and Benefits | Aon About AonAon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses. Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon's newsroom and sign up for news alerts here. Media Contactmediainquiries@ (U.S., Canada and Puerto Rico): +1 833 751 8114International: +1 312 381 3024 View original content to download multimedia: SOURCE Aon plc Sign in to access your portfolio
CNBC
30-04-2025
- Health
- CNBC
GLP-1s can help employers lower medical costs in 2 years, new study finds
The growing demand for diabetes and weight loss drugs like Mounjaro, Ozempic and Wegovy has helped fuel higher health costs for large employers. For many, the big question is whether the pricy medications known as GLP-1s will pay off by improving worker health and lowering overall health costs over time. Analysts at Aon say it's already happening. "We've never seen anything like this, really," said Greg Case, CEO of Aon, an employer benefits services firm. "There was a 44% reduction in major cardiovascular issues. There was substantial reduction in osteoporosis. There was substantial reduction in pneumonia of multiple types." Aon researchers found that within two years, improved health outcomes for patients who were taking GLP-1 drugs bends the cost curve on medical care for them and their employers. However, getting to those savings requires high upfront costs. GLP-1s come at a list price of more than $1,000 per dose. As broader approval for the drugs spurs higher demand, it's also causing employer drug spending to spike. Since 2023, GLP-1s have pushed costs up at a pace than high-priced specialty medications, which include costly cancer and autoimmune treatments, according to an analysis by Evernorth, a division of Cigna. Aon analysts looked at medical claims data for 139,000 U.S.-based workers with employer health coverage who took GLP-1 medications between 2022 and 2024. Beyond the drug costs, the study found GLP-1 patients tend to incur higher medical costs in their first year on the drugs, with more doctor visits to monitor their treatment on the drug and to seek help for other issues such as sleep apnea and esophageal conditions like acid reflux. "The increase comes about in the first 12 to 15 months," Case said. "They're getting remedies on things that actually are underlying conditions [of obesity]." But by the end of the second year of treatment with the GLP-1 drugs, overall health care costs for patients taking them fell 7% on average, compared to workers with similar chronic conditions and obesity characteristics who were not taking the drugs, Aon found. For GLP-1 patients who maintained rigorous adherence to the drug regimen, the savings were up to 13%. The biggest driver of those savings was the reduction by more than 40% of major adverse cardiac events such as heart attacks and strokes, compared to patients who were not taking the drugs, as well as a reduction in the onset of diabetes. Case said with this data, Aon has been able to help clients understand the timeline for seeing a return on providing insurance coverage for GLP-1s for weight loss, in addition to Type 2 Diabetes. "We saw every single place where the cost went down — and it's stunning," said Case. "You can do this in a way that has an ROI, that will literally be an economic return." Following its research, Aon has launched a subsidized GLP-1 weight management program for its own U.S. workforce, which includes weekly virtual wellness visits and home blood tests to help employees adhere to the drug regimen. The company will present the full results of its study at the Milken Institute Global Conference on Monday.
Yahoo
28-04-2025
- Business
- Yahoo
Aon attributable net income slips 10% in Q1 2025
Aon has recorded attributable net income of $965m for the first quarter of 2025 (Q1 2025), or $4.43 per diluted share, down 10% from $1.07bn, or $5.35 per diluted share, a year ago. The insurer achieved total revenue of $4.73bn, a 16% increase from $4.07bn in Q1 2024. Operating income remained steady at $1.46bn, nearly flat compared with $1.47bn in the prior year. However, Aon's adjusted operating income increased by 12% to $1.8bn for the quarter ending 31 March 2025. Total operating expenses rose 25% to $3.27bn from $2.60bn in Q1 2024, primarily due to a 19% increase in compensation and benefits and a significant rise in amortisation of intangible assets. Aon operates through two primary segments: Risk Capital, comprising commercial risk solutions and reinsurance solutions, and Human Capital, including health solutions and wealth solutions. The Risk Capital segment reported a revenue increase of 7% to $3.2bn, while the Human Capital segment's revenue grew by 40% to $1.5bn. Aon president and CEO Greg Case said: "Aon has momentum entering year two of the 3x3 Plan and our continued execution drove another quarter of mid-single-digit Organic revenue growth and strong operating performance. 'We are driving growth by providing actionable insights, powered by Aon Business Services, to our clients in an increasingly complex macro environment. These results reflect robust demand for our Risk Capital and Human Capital solutions. We are reaffirming our 2025 guidance, across all key metrics, reflecting the resilience and strength of our business and financial model." Aon said that its free cash flow generation has supported targeted 'tuck-in' acquisitions and a capital return of $397m to shareholders through dividends and share repurchases. Additionally, it has declared a 10% increase in its quarterly dividend, continuing a 15-year streak of dividend growth. For the full year of 2024, Aon's net income attributable to shareholders reached $2.65bn, a 4% increase from 2023. "Aon attributable net income slips 10% in Q1 2025 " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
